DeepMed Research

Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Metastatic Malignant Solid Neoplasm
Metastatic Melanoma
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Pathologic Stage IV Cutaneous Melanoma AJCC v8
Recurrent Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm
Uveal Melanoma
Acral Melanoma
Neuroendocrine Tumors
Paraganglioma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Fludeoxyglucose F-18
Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2019-10-08

Last Posted Date: 2025-04-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT04119024

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Stanford Cancer Institute, Stanford, California, United States

Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma

Phase 2

Terminated

Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
KRAS Protein Variant
Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Interventions: Biological: Cetuximab
Drug: Cisplatin
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Radiation Therapy

First Posted Date: 2019-09-27

Last Posted Date: 2023-06-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 1

Registration Number: NCT04106362

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Stereotactic Radiation Therapy Before Surgery for the Treatment of Resectable Brain Metastases

Not Applicable

Withdrawn

Conditions: Malignant Neoplasm, Brain
Brain Tumor

Interventions: Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Stereotactic Radiosurgery
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2019-08-28

Last Posted Date: 2022-01-31

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT04069910

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

OsteoCrete in Filling Bone Voids in Participants With Bone Voids or Defects

Not Applicable

Completed

Conditions: Health Status Unknown

Interventions: Other: Magnesium-based Bone Void Filler

First Posted Date: 2019-08-28

Last Posted Date: 2022-09-23

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 5

Registration Number: NCT04069923

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer

Phase 2

Completed

Conditions: Biochemically Recurrent Prostate Carcinoma
PSA Level Greater Than Fifty
PSA Progression
Stage IV Prostate Cancer AJCC v8
Prostate Adenocarcinoma
Prostate Carcinoma
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8
Metastatic Prostate Carcinoma

Interventions: Procedure: Computed Tomography
Drug: Gallium Ga 68-labeled PSMA-11
Procedure: Positron Emission Tomography
Other: Questionnaire Administration

First Posted Date: 2019-08-08

Last Posted Date: 2021-09-30

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 937

Registration Number: NCT04050215

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Phase 1

Active, not recruiting

Conditions: Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma
CD19 Positive
Refractory Chronic Lymphocytic Leukemia
Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Follicular Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Follicular Lymphoma

Interventions: Biological: Chimeric Antigen Receptor T-Cell Therapy
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Biological: Tocilizumab

First Posted Date: 2019-07-05

Last Posted Date: 2025-05-06

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 24

Registration Number: NCT04007029

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

SPECT/CT for the Characterization of Renal Masses

Recruiting

Conditions: Kidney Neoplasm
Renal Mass

Interventions: Procedure: Computed Tomography
Other: Questionnaire Administration
Procedure: Single Photon Emission Computed Tomography
Radiation: Technetium Tc-99m Sestamibi

First Posted Date: 2019-06-25

Last Posted Date: 2025-02-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 100

Registration Number: NCT03996850

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Early Phase 1

Completed

Conditions: Resectable Pancreatic Ductal Adenocarcinoma
Borderline Resectable Pancreatic Adenocarcinoma

Interventions: Drug: Fluorouracil
Drug: Irinotecan
Drug: Irinotecan Hydrochloride
Drug: Leucovorin
Drug: Leucovorin Calcium
Biological: Nivolumab
Drug: Oxaliplatin
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2019-05-31

Last Posted Date: 2024-08-09

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 28

Registration Number: NCT03970252

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors

Not Applicable

Active, not recruiting

Conditions: Anatomic Stage II Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Prognostic Stage I Breast Cancer AJCC v8
Prognostic Stage IIB Breast Cancer AJCC v8
Anatomic Stage I Breast Cancer AJCC v8
Postmenopausal
Prognostic Stage IB Breast Cancer AJCC v8

Interventions: Behavioral: Exercise Intervention
Dietary Supplement: Dietary Intervention
Other: Questionnaire Administration

First Posted Date: 2019-05-16

Last Posted Date: 2024-07-05

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 9

Registration Number: NCT03953157

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Acute Myelogenous Leukemia

Interventions: Drug: Gemtuzumab Ozogamicin
Drug: Liposome-encapsulated Daunorubicin-Cytarabine

First Posted Date: 2019-04-05

Last Posted Date: 2023-11-18

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 13

Registration Number: NCT03904251

Locations: 🇺🇸
University of California San Diego, San Diego, California, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy